TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33015912
Drug: 1-day low-residue
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-day low-residue diet (LRD) with standard laxative treatment
Study: 33015912
Drug: 3-day low-residue
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day low-residue diet (LRD) with standard laxative treatment
Study: 34655400
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium L‐threonate (MLT) for 12 weeks
Study: 34655400
Drug: High‐dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐dose intravenous (IV) magnesium sulfate (MgSO4) for 3 days followed by open‐label MLT for 24 weeks
Study: 33106853
Drug: Observational analysis;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational analysis; 1 µg/mL increase in plasma adiponectin
Study: 33106853
Drug: One-sample Mendelian
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-sample Mendelian randomization; 1 µg/mL genetically determined increase in plasma adiponectin
Study: 32641096
Drug: Vaginal patch
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal patch plastron
Study: 34468881
Drug: Initial invasive
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial invasive revascularization strategy with optimal medical therapy
Study: 38212104
Drug: CC+SI
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC+SI
Study: 32359899
Drug: ticagrelor +
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ticagrelor + aspirin
Study: 35229778
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral‐B Pro Health Gum care®)
Study: 35229778
Drug: Powered toothbrush
Normalized name: Pro Clean Spinbrush Powered Toothbrush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powered toothbrush (Oral‐B Cross action Power Dual®)
Study: 35778941
Drug: Cognitive-behavioral-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral-based physical therapy (CBPT) intervention, 6 sessions, telephone-based
Study: 35906549
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 30 Gy/5fx HSRT and 20 Gy/10fx IMRT with concurrent temozolomide and adjuvant chemotherapy
Study: 36078655
Drug: Mostly Linear
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mostly Linear (ML; 80% linear, 20% nonlinear)
Study: 32906135
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure treatment arm
Study: 32906135
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment arm
Study: 32594854
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (BR; 985 mg/d)
Study: 32594854
Drug: Nitrate-depleted beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-depleted beetroot juice (PLA; 0.37 mg/d)
Study: 35599701
Drug: Low-dose anticoagulation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose anticoagulation in acutely ill participants/intermediate-dose anticoagulation in critically ill participants
Study: 616518461
Drug: Bromocriptine 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5mg once daily
Study: 35305746
Drug: PACT-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: PACT-G
Study: 32750250
Drug: Liraglutide at
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide at a dose of 1.8 mg/d
Study: 36227352
Drug: THC-dominant cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC-dominant cannabis (13.75 mg THC)
Study: 36227352
Drug: THC/CBD-equivalent cannabis
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC/CBD-equivalent cannabis (13.75 mg THC/13.75 mg CBD)
Study: 36227352
Drug: CBD-dominant cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD-dominant cannabis (13.75 mg CBD)
Study: 33788464
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment at Dahe (KI 12), Zhongzhu (KI 15), Hegu (LI 4), Xuehai (SP 10) for 30 min, once a day, for 2 courses with 1-day interval.
Study: 33788464
Drug: Oral Xinshenghua
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Xinshenghua tablet, 4 tablets each time, 3 times a day for 7 days.
Study: 34318633
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 0.5 g dissolved in 20 ml normal saline injected into femoral bone marrow cavity for local treatment
Study: 34318633
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 20 minutes before operation, 15 mg/kg diluted in 250 ml sodium chloride injection, intravenous drip
Study: 32345916
Drug: Liposomal CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal CBD (20 mg/day)
Study: 32345916
Drug: Nonliposomal CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonliposomal CBD (50 mg/day)
Study: 35236397
Drug: Internet-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based Cognitive Behavioural Therapy (Reframe IT) for high-risk students
Study: 34131763
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy along with conventional management
Study: 36050653
Drug: Temozolomide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (50 mg/m2 for 3 months)
Study: 616116613
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment guided by VA stabilization
Study: 616116613
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment guided by disease activity
Study: 35083559
Drug: Novel balloon
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel balloon catheter dilation therapy
Study: 35083559
Drug: 14-Fr ordinary
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-Fr ordinary urinary catheter dilation therapy
Study: 33787926
Drug: Standard Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Behavioral Therapy (SBT)
Study: 32349117
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d oral tropisetron
Study: 32349117
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d oral tropisetron
Study: 32349117
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d oral tropisetron
Study: 33162246
Drug: Urethral bulking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urethral bulking agent injection
Study: 33151955
Drug: Intervention (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (low energy diet, exercise training, optimized treatment of hypertension, dyslipidemia, and diabetes)
Study: 35331641
Drug: Veliparib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (120 mg daily for 7 days/cycle) with carboplatin and paclitaxel
Study: 35331641
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (investigator's choice of platinum doublet chemotherapy, up to 6, 21-day cycles)
Study: 33288685
Drug: Low-dose endotoxin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose endotoxin (LPS) injection
Study: 33288685
Drug: LPS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS treatment in mice
Study: 32843515
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral pudendal nerve block (PNB) with 0.25% ropivacaine 10 mL
Study: 32843515
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with 10 mL saline
Study: 34295981
Drug: Placebo (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (140 mg)
Study: 32556768
Drug: Omeprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (80 mg/day intravenously for 3 days followed by 40 mg/day orally for 4 weeks)
Study: 34297677
Drug: Active Breaks
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Breaks Program (20 periods of weekly ABs, 5-10 minutes, 3-5 times a day for 17 weeks)
Study: 36102762
Drug: Senior Chef
Normalized name: docosahexaenoic acid / phosphatidylserine Oral Capsule [Senior Moment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senior Chef programme (SC group) - 8-week nutrition education and cooking class (3 hours weekly)
Study: 36102762
Drug: Steady As
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steady As You Go programme (SAYGO group) - 10-week strength and balance exercise programme (1 hour weekly)
Study: 33577011
Drug: Anti‐β2 glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐β2 glycoprotein I antibody IgA/G/M
Study: 32237143
Drug: Group game
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group game intervention including routine preoperative preparation and group game
Study: 36436532
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy with aerobic exercise (10 min aerobic exercise after nine 90‐min weekly sessions of exposure therapy)
Study: 36436532
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy with passive stretching (10 min passive stretching after nine 90‐min weekly sessions of exposure therapy)
Study: 32184123
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) 3 g intravenous infusion
Study: 32184123
Drug: Placebo (PL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL, 0.9% NaCl) intravenous infusion
Study: 35331007
Drug: Intensive BG
Normalized name: BG-777
DrugBank: BG-777 (DB05839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive BG control (target BG 80-130 mg/dL) for 72 hours
Study: 35331007
Drug: Standard BG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BG control (target BG 80-179 mg/dL) for 72 hours
Study: 34273114
Drug: Miscanthus planted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miscanthus planted in tilled soil amended with organic P (Class B biosolids applied at 45 Mg ha‐1)
Study: 33982083
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to antiretroviral therapy (ART)
Study: 34782191
Drug: Adjunctive oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive oral dexamethasone
Study: 33060531
Drug: Routine hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine hydration (1 ml/kg/h, 0.9% sodium chloride) for 3-12 hours before and 24 hours after contrast exposure
Study: 35110644
Drug: NeoRehab program
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeoRehab program (parent-provided interventions including vocal soothing, scent exchange, comforting touch, skin-to-skin care, massage, and physical therapy)
Study: 35980648
Drug: Individualised management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised management combined with drug treatment (silver ion alginate, hydrocolloid and foam dressings)
Study: 35980648
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (silver ion alginate, hydrocolloid and foam dressings)
Study: 35980648
Drug: Individualised management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised management combined with drug treatment
Study: 35843106
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of fructooligosaccharide (FOS)
Study: 35843106
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of partially hydrolyzed guar gum (PHGG)
Study: 35843106
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of digestible maltodextrin (placebo)
Study: 33470727
Drug: Daily financial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily financial incentives linked to real-time adherence monitoring
Study: 32333898
Drug: Satralizumab 120
Normalized name: satralizumab 120 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satralizumab 120 mg
Study: 33464762
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (1st line treatment)
Study: 33464762
Drug: Rituximab (2nd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (2nd line treatment)
Study: 32746841
Drug: Occupation-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupation-based intervention supported with problem-solving therapy
Study: 35449020
Drug: Tolvaptan (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (initial dose 7.5 mg)
Study: 35449020
Drug: Fluid restriction
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid restriction (initial limit 1000 ml per 24 h)
Study: 32314298
Drug: Topical antifungal
Normalized name: Imidazole and triazole derivatives, topical antifungals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antifungal agent + CO2 laser ablation once a month for the first 3 months
Study: 32314298
Drug: Topical antifungal
Normalized name: Imidazole and triazole derivatives, topical antifungals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antifungal agent
Study: 32314298
Drug: Topical antifungal
Normalized name: Imidazole and triazole derivatives, topical antifungals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antifungal agent + CO2 laser ablation
Study: 33966560
Drug: BARKH-based algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: BARKH-based algorithm for identification and treatment of hypertensive emergencies
Study: 34669179
Drug: Sonidegib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib 800 mg once daily
Study: 34582281
Drug: Treatment seeking
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment seeking participants
Study: 34582281
Drug: Non-treatment seeking
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment seeking participants
Study: 32444309
Drug: SLOIT (slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLOIT (slow low-dose oral immunotherapy)
Study: 33798303
Drug: Baduanjin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baduanjin and auricular point sticking therapy
Study: 33798303
Drug: Estazolam 1
Normalized name: estazolam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam 1 mg, once daily for 12 days
Study: 37354048
Drug: Ritonavir 100
Normalized name: ritonavir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 100 mg
Study: 34658360
Drug: Intravenous thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolytic therapy with alteplase in addition to routine therapy (antiplatelet aggregation, statins, neuroprotection, and drugs that stimulate blood flow)
Study: 34658360
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy (antiplatelet aggregation, statins, neuroprotection, and drugs that stimulate blood flow)
Study: 34658360
Drug: Intravenous thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolytic therapy with alteplase in addition to routine therapy
Study: 34096012
Drug: Reduced ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced ticagrelor maintenance dose with or without acetylsalicylic acid (ASA) withdrawal
Study: 34096012
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose ticagrelor with dual antiplatelet treatment (DAPT)
Study: 32755273
Drug: Cannabidiol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol (600 mg oral dose)
Study: 32093757
Drug: Sensory intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory intervention (SI) to improve quality of life for PwD with concurrent hearing and/or vision impairment.
Study: 35061005
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine group (10 ml liposomal bupivacaine + 10 ml 0.5% bupivacaine)
Study: 35061005
Drug: Bupivacaine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine group (20 ml 0.5% bupivacaine)
Study: 32019584
Drug: Complementary horse-assisted
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary horse-assisted therapy (cHAT)
Study: 32019584
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU-only)
Study: 35944269
Drug: Brief psychoeducation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychoeducation intervention added to treatment-as-usual (n = 24)
Study: 35944269
Drug: Treatment-as-usual (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (control group, n = 27)
Study: 32684463
Drug: Stepwise reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise reduction in milk allowance (STEP: 8 L/d of MR from d 14 to 28; 5 L/d from d 29 to 42; 4 L/d from d 43 to 49; 2 L/d from d 50 to 56 of age)
Study: 32684463
Drug: Conventional flat-rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional flat-rate milk allowance (CON: 6.5 L/d of MR from d 14 to 42; 4 L/d from d 43 to 49; 2 L/d from d 50 to 56 of age)
Study: 32684463
Drug: Restricted portion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted portion size (RES: maximum milk portion size of 2.3 L/portion)
Study: 32684463
Drug: UNRES treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: UNRES treatment among CON calves
Study: 32959058
Drug: Bortezomib-containing chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib-containing chemotherapy (ADEB)
Study: 32470389
Drug: More-intensive renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: More-intensive renal replacement therapy (hemodialysis or sustained low-efficiency dialysis six times per week or continuous venovenous hemodiafiltration at 35 mL/kg per hour)
Study: 32470389
Drug: Less-intensive renal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less-intensive renal replacement therapy (hemodialysis or sustained low-efficiency dialysis three times per week or continuous venovenous hemodiafiltration at 20 mL/kg per hour)
Study: 32173464
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 500 mg
Study: 32173464
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 1200 mg
Study: 32173464
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 1200 mg (PD-L1-positive)
Study: 32173464
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 1200 mg (PD-L1-high)
Study: 32173464
Drug: Treatment-related adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related adverse events leading to discontinuation
Study: 34855648
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium patches (150 mg/day, increased to 225 mg/day)
Study: 34855648
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium patches
Study: 33683659
Drug: Targeted cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted cancer drugs as monotherapies
Study: 33683659
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies with targeted cancer drugs
Study: 32485781
Drug: 880 μg
Normalized name: mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 880 μg fluticasone furoate administered intranasally
Study: 35527579
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy (Control group)
Study: 33141477
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide econazole cream (TAEC)
Study: 36448744
Drug: Intralesional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroid
Study: 32773223
Drug: Triglyceride (TG)
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride (TG) levels ≥150 mg/dL
Study: 35894933
Drug: Tofogliflozin 20
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tofogliflozin 20 mg once daily